A brand-new efficient and precise high performance liquid Chromatographic Method for Simultaneous Estimation of Cidofovir and Famciclovir
The quantitative analysis of cidofovir and famciclovir using a Symmetry C-18 150x4.6mm, 3.5 column with a flow rate of 1ml/min has resulted in the development of a brand-new, effective, and exact high performance liquid chromatographic method. Acetonitrile and buffer are mixed in 60:40 ratios for the mobile stage, and the buffer is created by dissolving 1 mL of formic acid in 1 liter of HPLC water. The detection was done at a wavelength of 250 nm. After 8 minutes of running time, the Cidofovir and Famciclovir peaks were separated, with the former peak eluting after 2.8 minutes and the latter peak eluting after 6.4 minutes, respectively.The proposed method displays strong linearity in the concentration ranges of 7.5 g/ml to 112.5 g/ml for cidofovir and 25 g/ml to 375 g/ml for famciclovir. The findings of the precision and recovery examinations range from 98 to 102%. The percent RSD is less than 2.0% in any robustness scenario. Under pressure, deterioration has little impact, and solutions remain effective for the entire day. The parameters of precision, accuracy, specificity, stability, robustness, linearity, limit of detection, and limit of quantification were evaluated and found to be within the acceptable range when the method was devised and validated in accordance with ICH guidelines.
2. Cheeran, Maxim C, Lokensgard, James R, Schleiss, Mark R, 2009. Neuropathogenesis of Congenital Cytomegalovirus Infection: Disease Mechanisms and Prospects for Intervention. Clinical Microbiology Reviews, 22(1):99–126.
3. Muftuoglu, Muharrem, Olson, Amanda, Marin, David et al, 2018. Allogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine, 379(15):1443–1451.
4. De Gascun C. F, Carr M. J, 2013. Human polyomavirus reactivation: Disease pathogenesis and treatment approaches. Clinical and Developmental Immunology, 2013:1–27.
5. Bradbury J, 2002. Orally available cidofovir derivative active against smallpox. Lancet, 359(9311):1041.
6. Nagel M. A, Gilden D. H, 2007. The protean neurologic manifestations of varicella-zoster virus infection. Cleveland Clinic Journal of Medicine, 74(7):489–94,496,498–9 passim.
7. Magee WC, Hostetler KY, Evans DH, 2005. Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir Diphosphate. Antimicrobial Agents and Chemotherapy, 49(8):3153–3162.
8. Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR, 2006. Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy. Pediatr Transplant, 10(1):32–7.
9. Grinde B, 2013. Herpesviruses: latency and reactivation - viral strategies and host response. Journal of Oral Microbiology, 5(1):22766.
10. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al, 1995. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Annals of Internal Medicine, 123(2):89–96.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.